Platinum-resistant Ovarian Cancer| A Pipeline Analysis Report 2018 by Technavio | Financial Buzz

Platinum-resistant Ovarian Cancer| A Pipeline Analysis Report 2018 by Technavio

has announced their latest pipeline analysis report on the platinum-resistant
ovarian cancer market. The report includes a detailed analysis
of the pipeline molecules under investigation within the defined data
collection period to treat platinum-resistant ovarian cancer.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for platinum-resistant ovarian cancer, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report presents a detailed analysis of the market, including
regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the coming years.

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

Platinum-resistant ovarian cancer: Market

Platinum-resistant ovarian cancer is a highly fatal disease and is the
eighth most common cause of death in women. Patients with ovarian cancer
have less than 47.4% chances of surviving for more than five years as
per the analysis based on the data collected between 2008 and 2014.
Though various chemotherapy drugs are available for the treatment of the
disease, about 90% of all types of ovarian cancer become resistant to
platinum and recur in six months of treatment, which makes it a deadly

According to a senior analyst at Technavio for research on oncology,
“The prevalence of ovarian cancer are not evenly spread across the
world. It is more common in less developed countries with more developed
nations. Nearly 58% of ovarian cancer cases are from less developed

Platinum-resistant ovarian cancer segmentation

This market research report segments the platinum-resistant ovarian
cancer market based on therapies employed that includes combination
therapy and monotherapy, RoA (intravenous, oral, subcutaneous,
intradermal, intraperitoneal, and unknown), therapeutic modalities
(monoclonal antibody, small molecules, vaccine, marine-derived,
adenovirus, gene therapy, and undisclosed), targets for drugs under
development (programmed cell death 1, PARP, VEGF, CSF1, DNA, folate
receptor alpha, unknown, and others), MoA (PDCD1 inhibitor, PARP
inhibitor, VEGF inhibitor, CSF1 inhibitor, DNA inhibitor, folate
receptor alpha antagonist, unknown, and others) drugs under development
(pre-clinical, phase I, phase Ia, phase I/II, phase II, and phase III),
and recruitment status (recruiting, active not recruiting, not yet
recruiting, completed, and undisclosed). It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View source version on